FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark MULLIGAN

Research Profile

Living Beings

Chemicals & Drugs

Disorders

HIV Infections

Anatomy

Concepts & Ideas

Molecular Sequence Data

Procedures

Physiology

Lymphocyte Activation

Genes & Molecular Sequences

Amino Acid Sequences

Co-author Network

Publications

TOP 3
Srilatha Edupuganti; Rachel Barwick Eidex; Harry L Keyserling; Robert S Lanciotti; Harvey B Lipman; Mark MULLIGAN; Walter Orenstein; Yi Pan; Troy D Querec; Dirk Teuwen; Rafi Ahmed; Rama S Akondy; Alan Barrett; Martin S Cetron; Carlos del Rio
A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.
Jennifer A Whitaker; Nadine G Rouphael; Srilatha Edupuganti; Lilin Lai; Mark MULLIGAN
Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1.
Katherine Gibney; Olga I Kosoy; Robert S Lanciotti; Mark MULLIGAN; Amanda J Panella; Mark J Delorey; Srilatha Edupuganti; Marc Fischer; J Erin Staples
Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark MULLIGAN (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Srilatha Edupuganti; Rachel Barwick Eidex; Harry L Keyserling; Robert S Lanciotti; Harvey B Lipman; Mark MULLIGAN; Walter Orenstein; Yi Pan; Troy D Querec; Dirk Teuwen; Rafi Ahmed; Rama S Akondy; Alan Barrett; Martin S Cetron; Carlos del Rio
A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.
The American journal of tropical medicine and hygiene 2013;88(1):172-7.
2012: Jennifer A Whitaker; Nadine G Rouphael; Srilatha Edupuganti; Lilin Lai; Mark MULLIGAN
Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1.
The Lancet infectious diseases 2012;12(12):966-76.
2012: Katherine Gibney; Olga I Kosoy; Robert S Lanciotti; Mark MULLIGAN; Amanda J Panella; Mark J Delorey; Srilatha Edupuganti; Marc Fischer; J Erin Staples
Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.
The American journal of tropical medicine and hygiene 2012;87(6):1112-5.
2012: Lisa A Jackson; Harry L Keyserling; Karen L Kotloff; Mark MULLIGAN; Diana L Noah; Nadine Rouphael; Jack T Stapleton; Anna Wald; Patricia L Winokur; Rebecca C Brady; Wilbur H Chen; Cornelia L Dekker; Srilatha Edupuganti; Heather Hill; Mark C Wolff
Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.
The Journal of infectious diseases 2012;206(6):811-20.
2012: Gui-Mei Li; Megan McCausland; Aneesh K Mehta; Mark MULLIGAN; Xinyan Qu; Patrick C Wilson; Jens Wrammert; Jonathan W Yewdell; Nai-Ying Zheng; Sarah F Andrews; Christopher Chiu; Suman Das; Srilatha Edupuganti; Min Huang; Jane-Hwei Lee; Rafi Ahmed
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(23):9047-52.
2011: Robert B Belshe; Sharon E Frey; Irene Graham; Mark MULLIGAN; Srilatha Edupuganti; Lisa A Jackson; Anna Wald; Gregory Poland; Robert Jacobson; Harry Keyserling; Paul Spearman; Heather Hill; Mark Wolff
Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.
The Journal of infectious diseases 2011;203(5):666-73.
2011: Jens Wrammert; Dimitrios Koutsonanos; Gui-Mei Li; Srilatha Edupuganti; Jianhua Sui; Michael Morrissey; Megan McCausland; Ioanna Skountzou; Mady Hornig; W Ian Lipkin; Aneesh Mehta; Behzad Razavi; Carlos Del Rio; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Zahida Ali; Kaval Kaur; Sarah Andrews; Rama Rao Amara; Youliang Wang; Suman Das; Christopher David O'Donnell; Jon W Yewdell; Kanta Subbarao; Wayne A Marasco; Mark MULLIGAN; Richard W Compans; Rafi Ahmed; Patrick C Wilson
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.
The Journal of experimental medicine 2011;208(1):181-93.
2010: Paula M Frew; Matthew Archibald; Dazon Dixon Diallo; Su-I Hou; Takeia Horton; Kayshin Chan; Mark MULLIGAN; Carlos del Rio
An extended model of reasoned action to understand the influence of individual- and network-level factors on African Americans' participation in HIV vaccine research.
Prevention science : the official journal of the Society for Prevention Research 2010;11(2):207-18.
2009: Rama S Akondy; Nathan D Monson; Joseph D Miller; Srilatha Edupuganti; Dirk Teuwen; Hong Wu; Farah Quyyumi; Seema Garg; John D Altman; Carlos Del Rio; Harry L Keyserling; Alexander Ploss; Charles M Rice; Walter A Orenstein; Mark MULLIGAN; Rafi Ahmed
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(12):7919-30.
2009: Russell D Bradford; April C Pettit; Patty W Wright; Mark MULLIGAN; Larry W Moreland; David A McLain; John W Gnann; Karen C Bloch
Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(6):924-7.
2009: Mark MULLIGAN
Mark Mulligan leads Emory swine flu vaccine trial. Interview by Brooke Grindlinger.
The Journal of clinical investigation 2009;119(9):2438.
2009: Mark MULLIGAN
Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions.
Current infectious disease reports 2009;11(5):399-406.
2009: Gregory A Poland; Mark MULLIGAN
The imperative of influenza vaccines for elderly individuals-an evolving story.
The Journal of infectious diseases 2009;200(2):161-3.
2009: Paula M Frew; Carlos del Rio; Lu Lu; Sarah Clifton; Mark MULLIGAN
Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial.
Journal of acquired immune deficiency syndromes (1999) 2009;50(3):314-9.
2009: Clayton D Harro; Michael N Robertson; Michelle A Lally; Lori D O'Neill; Srilatha Edupuganti; Paul A Goepfert; Mark MULLIGAN; Frances H Priddy; Sheri A Dubey; Lisa S Kierstead; Xiao Sun; Danilo R Casimiro; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Devan V Mehrotra
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
AIDS research and human retroviruses 2009;25(1):103-14.
2009: Troy D Querec; Rama S Akondy; Eva K Lee; Weiping Cao; Helder I Nakaya; Dirk Teuwen; Ali Pirani; Kim Gernert; Jiusheng Deng; Bruz Marzolf; Kathleen Kennedy; Haiyan Wu; Soumaya Bennouna; Herold Oluoch; Joseph Miller; Ricardo Z Vencio; Mark MULLIGAN; Alan Aderem; Rafi Ahmed; Bali Pulendran
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans.
Nature immunology 2009;10(1):116-25.
2008: Nina Marano; Brian D Plikaytis; Stacey W Martin; Charles Rose; Vera A Semenova; Sandra K Martin; Alison E Freeman; Han Li; Mark MULLIGAN; Scott D Parker; Janiine Babcock; Wendy A Keitel; Hana El Sahly; Gregory A Poland; Robert M Jacobson; Harry L Keyserling; Stephen D Soroka; Sarah P Fox; John L Stamper; Michael M McNeil; Bradley A Perkins; Nancy Messonnier; Conrad P Quinn
Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.
JAMA : the journal of the American Medical Association 2008;300(13):1532-43.
2008: Paula M Frew; Carlos del Rio; Sarah Clifton; Matthew Archibald; Joseph T Hormes; Mark MULLIGAN
Factors influencing HIV vaccine community engagement in the urban South.
Journal of community health 2008;33(4):259-69.
2008: Joseph D Miller; Robbert van der Most; Rama S Akondy; John T Glidewell; Sophia Albott; David Masopust; Kaja Murali-Krishna; Patryce L Mahar; Srilatha Edupuganti; Susan Lalor; Stephanie Germon; Carlos del Rio; Mark MULLIGAN; Silvija I Staprans; John D Altman; Mark B Feinberg; Rafi Ahmed
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.
Immunity 2008;28(5):710-22.
2007: Nina D Russell; Barney S Graham; Michael C Keefer; M Juliana McElrath; Steven G Self; Kent J Weinhold; David C Montefiori; Guido Ferrari; Helen Horton; Georgia D Tomaras; Sanjay Gurunathan; Lynn Baglyos; Sharon E Frey; Mark MULLIGAN; Clayton D Harro; Susan P Buchbinder; Lindsey R Baden; William A Blattner; Beryl A Koblin; Lawrence Corey
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
Journal of acquired immune deficiency syndromes (1999) 2007;44(2):203-12.
2007: Tong-Ming Fu; Sheri A Dubey; Devan V Mehrotra; Daniel C Freed; Wendy Trigona; Lisa Adams-Muhler; James H Clair; Thomas G Evans; Roy T Steigbigel; Jeffrey M Jacobson; Paul A Goepfert; Mark MULLIGAN; Spyros A Kalams; Charles Rinaldo; Lan Zhu; Kara S Cox; Liming Guan; Romnie Long; Natasha Persaud; Michael J Caulfield; Jerald C Sadoff; Emilio A Emini; Scott Thaler; John W Shiver
Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.
AIDS research and human retroviruses 2007;23(1):67-76.
2006: Mark MULLIGAN; Nina D Russell; Connie Celum; J Kahn; E Noonan; David C Montefiori; Guido Ferrari; Kent J Weinhold; J M Smith; Rama Rao Amara; Harriet L Robinson
Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.
AIDS research and human retroviruses 2006;22(7):678-83.
2005: Anju Bansal; Ethan Gough; Steffanie Sabbaj; Doug Ritter; Karina Yusim; Greg Sfakianos; Grace M Aldrovandi; Richard A Kaslow; Craig M Wilson; Mark MULLIGAN; J. Michael Kilby; Paul A Goepfert
CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.
AIDS (London, England) 2005;19(3):241-50.
2004: Jiri Mestecky; Susan Jackson; Zina Moldoveanu; Lorie R Nesbit; Rose Kulhavy; Shirley J Prince; Steffanie Sabbaj; Mark MULLIGAN; Paul A Goepfert
Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals.
AIDS research and human retroviruses 2004;20(9):972-88.
2004: Deborah Lee; Barney S Graham; Ya-Lin Chiu; Peter B Gilbert; M Juliana McElrath; Robert B Belshe; Susan P Buchbinder; Haynes W Sheppard; Beryl A Koblin; Kenneth H Mayer; Michael C Keefer; Mark MULLIGAN; Connie Celum
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
The Journal of infectious diseases 2004;190(5):903-7.
2003: Anju Bansal; Steffanie Sabbaj; Bradley H Edwards; Doug Ritter; Christopher Perkins; James Tang; James J Szinger; Heidi Weiss; Paul A Goepfert; Bette Korber; Craig M Wilson; Richard A Kaslow; Mark MULLIGAN
T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles.
AIDS research and human retroviruses 2003;19(11):1017-26.
2003: Steffanie Sabbaj; Anju Bansal; G Douglas Ritter; Christopher Perkins; Bradley H Edwards; Ethan Gough; Jianming "James" Tang; James J Szinger; Bette Korber; Craig M Wilson; Richard A Kaslow; Mark MULLIGAN; Paul A Goepfert
Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities.
Journal of acquired immune deficiency syndromes (1999) 2003;33(4):426-38.
2003: Kit L Shaw; Dirk Lindemann; Mark MULLIGAN; Paul A Goepfert
Foamy virus envelope glycoprotein is sufficient for particle budding and release.
Journal of virology 2003;77(4):2338-48.
2002: Jianming "James" Tang; Craig M Wilson; Shreelatha Meleth; Angela Myracle; Elena Lobashevsky; Mark MULLIGAN; Steven D Douglas; Bette Korber; Sten Vermund; Richard A Kaslow
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents.
AIDS (London, England) 2002;16(17):2275-84.
2002: Steffanie Sabbaj; Bradley H Edwards; Mrinal K Ghosh; Katherine Semrau; Sanford Cheelo; Donald M Thea; Louise Kuhn; G Douglas Ritter; Mark MULLIGAN; Paul A Goepfert; Grace M Aldrovandi
Human immunodeficiency virus-specific CD8(+) T cells in human breast milk.
Journal of virology 2002;76(15):7365-73.
2002: Kalpana Gupta; Michael G Hudgens; Lawrence Corey; M Juliana McElrath; Kent J Weinhold; David C Montefiori; Geoffrey J Gorse; Sharon E Frey; Michael C Keefer; Thomas G Evans; Raphael Dolin; David H Schwartz; Clayton D Harro; Barney Graham; Paul Spearman; Mark MULLIGAN; Paul A Goepfert
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.
Journal of acquired immune deficiency syndromes (1999) 2002;29(3):254-61.
2002: Bradley H Edwards; Anju Bansal; Steffanie Sabbaj; Janna Bakari; Mark MULLIGAN; Paul A Goepfert
Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.
Journal of virology 2002;76(5):2298-305.
2001: Richard A Kaslow; Charles A Rivers; Jianming "James" Tang; T J Bender; Paul A Goepfert; Raphaelle El Habib; Kent J Weinhold; Mark MULLIGAN
Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines.
Journal of virology 2001;75(18):8681-9.
2001: Robert B Belshe; C Stevens; Geoffrey J Gorse; Susan Buchbinder; Kent J Weinhold; Haynes W Sheppard; Donald Stablein; S Self; James McNamara; Sharon Frey; J Flores; Jean-Louis Excler; M Klein; R E Habib; AM Duliege; Clayton D Harro; Lawrence Corey; Michael C Keefer; Mark MULLIGAN; P Wright; Connie Celum; Franklyn N Judson; K Mayer; David J McKirnan; Michael Marmor; George E Woody
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
The Journal of infectious diseases 2001;183(9):1343-52.
2001: John S Lambert; Michael C Keefer; Mark MULLIGAN; David H Schwartz; Jiri Mestecky; Kent J Weinhold; C Smith; RH Hsieh; Zina Moldoveanu; Patricia Fast; B Forrest; W Koff
A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.
Vaccine 2001;19(23-24):3033-42.
2001: Thomas G Evans; M Juliana McElrath; T Matthews; David Montefiori; Kent J Weinhold; Mark Wolff; Michael C Keefer; Esper Kallas; Lawrence Corey; Geoffrey J Gorse; Robert B Belshe; Barney S Graham; Paul Spearman; David H Schwartz; Mark MULLIGAN; Paul A Goepfert; Patricia Fast; Phillip W. Berman; M Powell; D Francis
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
Vaccine 2001;19(15-16):2080-91.
2000: Paul A Goepfert; Anju Bansal; Bradley H Edwards; G Douglas Ritter; I Tellez; Sylvia A McPherson; Steffanie Sabbaj; Mark MULLIGAN
A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.
Journal of virology 2000;74(21):10249-55.
2000: Steffanie Sabbaj; Mark MULLIGAN; RH Hsieh; Robert B Belshe; Jerry R McGhee
Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group.
AIDS (London, England) 2000;14(10):1365-74.
2000: Anju Bansal; Kit L Shaw; Bradley H Edwards; Paul A Goepfert; Mark MULLIGAN
Characterization of the R572T point mutant of a putative cleavage site in human foamy virus Env.
Journal of virology 2000;74(6):2949-54.
1999: G Wang; Mark MULLIGAN; DN Baldwin; Maxine L Linial
Endogenous virus of BHK-21 cells complicates electron microscopy studies of foamy virus maturation.
Journal of virology 1999;73(10):8917.
1999: Paul A Goepfert; K Shaw; G Wang; Anju Bansal; Bradley H Edwards; Mark MULLIGAN
An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes.
Journal of virology 1999;73(9):7210-7.
1999: Thomas G Evans; Michael C Keefer; Kent J Weinhold; Mark Wolff; David Montefiori; Geoffrey J Gorse; Barney S Graham; M Juliana McElrath; Mary Lou Clements-Mann; Mark MULLIGAN; Patricia Fast; MC Walker; Jean-Louis Excler; AM Duliege; Jim Tartaglia
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
The Journal of infectious diseases 1999;180(2):290-8.
1999: Mark MULLIGAN; J Weber
Human trials of HIV-1 vaccines.
AIDS (London, England) 1999;13 Suppl A():S105-12.
1999: G Wang; Mark MULLIGAN
Comparative sequence analysis and predictions for the envelope glycoproteins of foamy viruses.
The Journal of general virology 1999;80 ( Pt 1)():245-54.
1998: Robert B Belshe; Geoffrey J Gorse; Mark MULLIGAN; Thomas G Evans; Michael C Keefer; Jean-Louis Excler; AM Duliege; Jim Tartaglia; W I Cox; James McNamara; K L Hwang; A Bradney; David Montefiori; Kent J Weinhold
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
AIDS (London, England) 1998;12(18):2407-15.
1998: K Salzwedel; John T West; Mark MULLIGAN; Eric Hunter
Retention of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum does not redirect virus assembly from the plasma membrane.
Journal of virology 1998;72(9):7523-31.
1998: A M Giddings; G D Ritter; Mark MULLIGAN
The matrix protein of HIV-1 is not sufficient for assembly and release of virus-like particles.
Virology 1998;248(1):108-16.
1998: Barney S Graham; M Juliana McElrath; Ruth I Connor; David H Schwartz; Geoffrey J Gorse; Michael C Keefer; Mark MULLIGAN; TJ Matthews; Steven Wolinsky; David C Montefiori; Sten Vermund; John S Lambert; Lawrence Corey; Robert B Belshe; Raphael Dolin; Peter F Wright; Bette T Korber; M C Wolff; Patricia Fast
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
The Journal of infectious diseases 1998;177(2):310-9.
1998: J Tello; Seng-Jaw Soong; B Hunter; Rebecca A. Meriwether; Edward W Hook; Mark MULLIGAN
HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic.
The American journal of the medical sciences 1998;315(1):11-6.
1997: R Paul Johnson; RL Glickman; J Q Yang; Amitinder Kaur; J T Dion; Mark MULLIGAN; Ronald C Desrosiers
Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.
Journal of virology 1997;71(10):7711-8.
1997: J M Ball; Mark MULLIGAN; Richard W Compans
Basolateral sorting of the HIV type 2 and SIV envelope glycoproteins in polarized epithelial cells: role of the cytoplasmic domain.
AIDS research and human retroviruses 1997;13(8):665-75.
1997: Paul A Goepfert; Kit L Shaw; G Douglas Ritter; Mark MULLIGAN
A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum.
Journal of virology 1997;71(1):778-84.
1996: Paul A Goepfert; G D Ritter; X Peng; A A Gbakima; Y Zhang; Mark MULLIGAN
Analysis of west African hunters for foamy virus infections.
AIDS research and human retroviruses 1996;12(18):1725-30.
1996: G D Ritter; G Yamshchikov; S J Cohen; Mark MULLIGAN
Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.
Journal of virology 1996;70(4):2669-73.
1995: Paul A Goepfert; G Wang; Mark MULLIGAN
Identification of an ER retrieval signal in a retroviral glycoprotein.
Cell 1995;82(4):543-4.
1995: J M Ball; Zina Moldoveanu; L R Melsen; P A Kozlowski; Susan Jackson; Mark MULLIGAN; Jiri Mestecky; Richard W Compans
A polarized human endometrial cell line that binds and transports polymeric IgA.
In vitro cellular & developmental biology. Animal 1995;31(3):196-206.
1994: R B Belshe; D P Bolognesi; M L Clements; L Corey; R Dolin; J Mestecky; Mark MULLIGAN; D Stablein; P Wright
HIV infection in vaccinated volunteers.
JAMA : the journal of the American Medical Association 1994;272(6):431.
1994: C P Spies; G D Ritter; Mark MULLIGAN; Richard W Compans
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain.
Journal of virology 1994;68(2):585-91.
1993: G D Ritter; Mark MULLIGAN; S L Lydy; Richard W Compans
Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain.
Virology 1993;197(1):255-64.
1993: Preston A Marx; Richard W Compans; Agegnehu Gettie; Jay K Staas; R M Gilley; Mark MULLIGAN; G V Yamshchikov; D Chen; John H Eldridge
Protection against vaginal SIV transmission with microencapsulated vaccine.
Science (New York, N.Y.) 1993;260(5112):1323-7.
1992: Mark MULLIGAN; G V Yamshchikov; G D Ritter; Feng Gao; M J Jin; C D Nail; C P Spies; Beatrice H Hahn; Richard W Compans
Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types.
Journal of virology 1992;66(6):3971-5.
1992: Mark MULLIGAN; G D Ritter; M A Chaikin; G V Yamshchikov; P Kumar; Beatrice H Hahn; Raymond W Sweet; Richard W Compans
Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex.
Virology 1992;187(1):233-41.
1991: D E Wells; S Chatterjee; Mark MULLIGAN; Richard W Compans
Inhibition of human immunodeficiency virus type 1-induced cell fusion by recombinant human interferons.
Journal of virology 1991;65(11):6325-30.
1990: R J Owens; C C Tanner; Mark MULLIGAN; Ranga Srinivas; Richard W Compans
Oligopeptide inhibitors of HIV-induced syncytium formation.
AIDS research and human retroviruses 1990;6(11):1289-96.
1990: Mark MULLIGAN; P Kumar; H X Hui; R J Owens; G D Ritter; Beatrice H Hahn; Richard W Compans
The env protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation.
AIDS research and human retroviruses 1990;6(6):707-20.
1989: Mark MULLIGAN; C G Cobbs
Bacteriostatic versus bactericidal activity.
Infectious disease clinics of North America 1989;3(3):389-98.
1988: Mark MULLIGAN; R Vasu; C E Grossi; E F Prasthofer; F M Griffin; A Kapila; J M Trupp; J C Barton
Neoplastic meningitis with eosinophilic pleocytosis in Hodgkin's disease: a case with cerebellar dysfunction and a review of the literature.
The American journal of the medical sciences 1988;296(5):322-6.